Welcome to Markets Desk, your midday read on what's moving markets and why.
Morgan Stanley is warning investors that the semiconductor cooldown is more than a blip. The once-dominant chip trade has lost momentum over the past several weeks, and the bank sees that weakness spreading into broader equity markets. Strategists are rotating toward more defensive sectors as volatility builds heading into the back half of the year.
Staying in the chip space, ASML is drawing renewed attention as arguably the most structurally important name in artificial intelligence infrastructure. The Dutch equipment maker holds a genuine monopoly on extreme ultraviolet lithography, the technology that makes advanced chips possible at all. Its High-NA platform and geopolitical insulation make it a long-term conversation that goes well beyond near-term semiconductor sentiment.
And on the healthcare side, the debate between CRISPR Therapeutics and Viking Therapeutics is sharpening as investors look ahead to two thousand twenty six. CRISPR has crossed a meaningful threshold, becoming the first company to bring a CRISPR-based gene therapy to commercial approval, which reframes the risk profile considerably for a name that was long treated as pure speculation.
That's the tape. Markets Desk, signing off the floor.
